COMMUNIQUÉS West-GlobeNewswire

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/05/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mai 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth [...]
Zelluna ASA activates first clinical site for ZIMA-101, marking entry into clinical execution
06/05/2026
Oslo, 6 May 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the first [...]
Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
LEXINGTON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
argenx to Present at BofA Securities 2026 Health Care Conference
06/05/2026
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen [...]
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
06/05/2026
ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments Q1 sales of $30.9 [...]
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 [...]
Zevra Reports First Quarter 2026 Financial Results and Corporate Update
06/05/2026
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to [...]
LifeMD Reports First Quarter 2026 Results
06/05/2026
First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in line, respectively, with the Company’s guidance. Gross margin increased approximately 420 basis points to 88%, versus [...]
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
06/05/2026
Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and Immunogenicity Data [...]
Monthly information on share capital and company voting rights
06/05/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital [...]
BiomX’s Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand
06/05/2026
Transforms fragmented communication into real-time, AI-driven coordination, assignment, and guided response NETANYA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE: PHGE) (“BiomX” or the “Company”) today [...]
Clover Health Reports First Quarter 2026 Results
06/05/2026
Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare [...]
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
06/05/2026
Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation [...]
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
06/05/2026
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra- [...]
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
06/05/2026
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
06/05/2026
PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission [...]
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
06/05/2026
Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales [...]
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
06/05/2026
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3) [...]

Pages